ROSEN, A LEADING LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Rosen Law Firm is urging investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, which the FDA found was malfunctioning and dosing patients with dangerously high insulin levels. The firm claims thousands of complaints were filed with the FDA, contradicting defendants' assertions that issues were benign. The lead plaintiff deadline is November 3, 2026.